Effect of eicosapentaenoic acid on central systolic blood pressure.

Toshiro Iketani, Kenji Takazawa, Akira Yamashina

Internal Medicine, Iketani Clinic, 3-7, Akigawa 1, Akiruno-shi, Tokyo 197-0804 Japan. et@apple.email.ne.jp

Prostaglandins, leukotrienes, and essential fatty acids 2013 Feb

filter terms:

Central systolic blood pressure (C-SBP) has been shown to be a better predictor of cardiovascular risk than brachial SBP. In this study, the effects of eicosapentaenoic acid (EPA) on C-SBP were compared with pravastatin. Twenty-four patients with hyperlipidemia were assigned 13 to receive 1800 mg/day EPA (EPA group) and 11 to receive 10 mg/day pravastatin (pravastatin group) for 3 months. In the EPA group, there were no changes in the LDL-cholesterol level. However, the radial augmentation index (AI) and C-SBP decreased after treatment by 5.7% (p < 0.01) and 8.7% (p < 0.001), respectively. Moreover, systolic and diastolic brachial BPs decreased by 7.1% and 8.0%, respectively (p < 0.01 for both). In the pravastatin group, the LDL-cholesterol level decreased by 29.5% (p < 0.001). However, there were no significant changes in brachial BP, AI and C-SBP between. These results suggested that EPA but not pravastatin may reduce cardiac afterload by reducing vascular reflected waves and lowering C-SBP. Copyright © 2012 Elsevier Ltd. All rights reserved.

Citation

Toshiro Iketani, Kenji Takazawa, Akira Yamashina. Effect of eicosapentaenoic acid on central systolic blood pressure. Prostaglandins, leukotrienes, and essential fatty acids. 2013 Feb;88(2):191-5